earnings
CH
NASDAQ · CHRS
Coherus Oncology, Inc.
Healthcare · Biotechnology
$1.42
Up+$0.10 (+7.58%)
Updated Aug 22, 2026, 3:36 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 165.18M
- P/E ratio
- 1.07
- Dividend yield
- 0.00%
- 52-week range
- $1.13 – $2.11
- Volume
- 1.57M
- Avg. volume
- 1.23M
Price performance
CHRS price history
1M range · 21 trading sessions · Daily adjusted prices
CHRS closed at $1.42 after 21 trading sessions, up 0.71% for the selected period.
- Last close
- $1.42
- Period change
- +0.71%
- Period low
- $1.14
- Period high
- $1.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.32 | $1.44 | $1.315 | $1.42 | 1.57M |
| Aug 20, 2026 | $1.31 | $1.34 | $1.27 | $1.32 | 740.19K |
| Aug 19, 2026 | $1.379 | $1.405 | $1.295 | $1.33 | 3.04M |
| Aug 18, 2026 | $1.26 | $1.36 | $1.22 | $1.34 | 3.48M |
| Aug 17, 2026 | $1.20 | $1.2001 | $1.13 | $1.15 | 1.26M |
| Aug 14, 2026 | $1.16 | $1.205 | $1.14 | $1.20 | 648.33K |
| Aug 13, 2026 | $1.18 | $1.195 | $1.13 | $1.14 | 1.06M |
| Aug 12, 2026 | $1.21 | $1.2462 | $1.17 | $1.17 | 1.16M |
| Aug 11, 2026 | $1.25 | $1.2599 | $1.18 | $1.21 | 968.34K |
| Aug 10, 2026 | $1.33 | $1.34 | $1.23 | $1.24 | 978.46K |
| Aug 7, 2026 | $1.27 | $1.40 | $1.24 | $1.27 | 1.6M |
| Aug 6, 2026 | $1.385 | $1.455 | $1.131 | $1.265 | 3.72M |
| Aug 5, 2026 | $1.48 | $1.525 | $1.435 | $1.45 | 999.32K |
| Aug 4, 2026 | $1.43 | $1.50 | $1.43 | $1.48 | 617.72K |
| Aug 3, 2026 | $1.42 | $1.4591 | $1.414 | $1.44 | 477.28K |
| Jul 31, 2026 | $1.48 | $1.48 | $1.40 | $1.41 | 437.18K |
| Jul 30, 2026 | $1.42 | $1.485 | $1.415 | $1.47 | 509.55K |
| Jul 29, 2026 | $1.44 | $1.475 | $1.40 | $1.41 | 570.98K |
| Jul 28, 2026 | $1.46 | $1.47 | $1.415 | $1.44 | 387.63K |
| Jul 27, 2026 | $1.46 | $1.495 | $1.44 | $1.46 | 456.66K |
| Jul 24, 2026 | $1.44 | $1.445 | $1.395 | $1.41 | 446.4K |
Latest CHRS news
The latest Smart Investors Daily articles mentioning CHRS.
Stock researchCompany · Forecast
Loading stock research…